Rapid Point-of-Care Testing for Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type (Lateral Flow Immunoassay, Paper-based Rapid Diagnostics), By Technology, By Age Group, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends
The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle ?-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.
POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the ?-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.
Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.
Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.
Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights
BIOMEDOMICS INC.
Silver Lake Research Corporation
Bio-Rad Laboratories, Inc.
Trivitron Healthcare
Hemex Health
Sysmex Corporation
EKF Diagnostics Holdings plc.
HemoCue America (Danaher)
Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends
The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle ?-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.
POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the ?-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.
Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.
Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.
Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights
- Based on type, the lateral flow immunoassay segment led the market in 2024 with a 51.66% share, due to its affordability, ease of use, and fast, accurate results. LFIA's ability to detect multiple hemoglobin variants and its suitability for low-resource settings contribute to its increasing adoption in global diagnostics.
- Based on technology, the hemoglobin electrophoresis segment led the market in 2024 with a 48.99% share, driven by its high accuracy in detecting hemoglobinopathies. As a reliable diagnostic method, it allows for precise identification of sickle cell disease and other hemoglobin variants, making it crucial for early intervention and disease management.
- Based on age group, the newborn screening (12 months and below) segment led the market in 2024 and is expected to witness the fastest CAGR during the forecast period, due to growing awareness and the importance of early diagnosis. Early detection through POC testing allows for prompt treatment, reducing complications and improving long-term outcomes for affected infants.
- The government laboratories sector type segment is experiencing significant growth, driven by national initiatives and technological advancements. The Indian Council of Medical Research (ICMR) has endorsed existing POC tests for sickle cell disease screening, encouraging states to implement one or two-level screening approaches.
- The hospitals & clinics end use segment is experiencing substantial growth, driven by the increasing prevalence of sickle cell disease and the demand for timely diagnostics.
- Based on distribution channel, the Business-to-Business (B2B) segment is experiencing significant growth, driven by increasing demand for accessible and efficient diagnostic solutions. Companies are forming strategic partnerships to expand their product offerings and reach broader markets.
- North America dominated the global Rapid point-of-care testing for sickle cell anemia industry with a revenue share of 43.97% in 2024, driven by increasing demand for accessible and efficient diagnostic solutions. This expansion is attributed to factors such as the rising prevalence of chronic diseases, advancements in diagnostic technologies, and increased funding from government and private institutions.
- Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease
BIOMEDOMICS INC.
Silver Lake Research Corporation
Bio-Rad Laboratories, Inc.
Trivitron Healthcare
Hemex Health
Sysmex Corporation
EKF Diagnostics Holdings plc.
HemoCue America (Danaher)
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. Age group
1.2.4. Sector Type
1.2.5. End Use
1.2.6. Distribution Channel
1.2.7. Regional scope
1.2.8. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Technology Outlook
2.2.3. Age Group Outlook
2.2.4. Sector Type
2.2.5. End Use Outlook
2.2.6. Distribution Channel
2.2.7. Regional outlook
2.3. Competitive Insights
CHAPTER 3. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for personalized medicine and genomic research
3.2.1.2. Growing prevalence of sickle cell disease (SCD)
3.2.1.3. Advancements in diagnostic technology
3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
3.2.2. Market restraint analysis
3.2.2.1. Limited accessibility to advanced technologies
3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Lateral Flow Immunoassay
4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Paper-Based Rapid Diagnostics
4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Others
4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hemoglobin Electrophoresis
5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Polymerase Chain Reaction (PCR)
5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Isothermal Amplification Assays
5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Newborn Screening (12 months and below)
6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Adult Screening (25 to 60 years)
6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Other Age Groups (1 to 25 & Above 60 years)
6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: SECTOR TYPE ESTIMATES & TREND ANALYSIS
7.1. Sector Type Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Government Labs
7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Private Labs
7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Corporate Labs
7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. PPP (Public-Private-Partnerships)
7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. End Use Market Share, 2024 & 2030
8.2. Segment Dashboard
8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Research Institutions
8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Hospitals & Clinics
8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. Diagnostic Laboratories
8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Homecare Settings
8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Others
8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
9.1. Distribution Channel Market Share, 2024 & 2030
9.2. Segment Dashboard
9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
9.4.1. B2B (Business-to-Business)
9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
9.4.2. B2C (Business-to-Consumer)
9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 10. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. North America: SWOT Analysis
10.5.2. U.S.
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework
10.5.2.3. Competitive scenario
10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
10.5.3. Canada
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework
10.5.3.3. Competitive scenario
10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.5.4. Mexico
10.5.4.1. Key country dynamics
10.5.4.2. Regulatory framework
10.5.4.3. Competitive scenario
10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.6. Europe
10.6.1. Europe: SWOT Analysis
10.6.2. UK
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework
10.6.2.3. Competitive scenario
10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
10.6.3. Germany
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework
10.6.3.3. Competitive scenario
10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
10.6.4. France
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework
10.6.4.3. Competitive scenario
10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
10.6.5. Italy
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework
10.6.5.3. Competitive scenario
10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
10.6.6. Spain
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework
10.6.6.3. Competitive scenario
10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
10.6.7. Norway
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework
10.6.7.3. Competitive scenario
10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
10.6.8. Sweden
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework
10.6.8.3. Competitive scenario
10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
10.6.9. Denmark
10.6.9.1. Key country dynamics
10.6.9.2. Regulatory framework
10.6.9.3. Competitive scenario
10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
10.7. Asia Pacific
10.7.1. Asia Pacific: SWOT Analysis
10.7.2. Japan
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework
10.7.2.3. Competitive scenario
10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
10.7.3. China
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework
10.7.3.3. Competitive scenario
10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
10.7.4. India
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework
10.7.4.3. Competitive scenario
10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
10.7.5. Australia
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework
10.7.5.3. Competitive scenario
10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
10.7.6. South Korea
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework
10.7.6.3. Competitive scenario
10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
10.7.7. Thailand
10.7.7.1. Key country dynamics
10.7.7.2. Regulatory framework
10.7.7.3. Competitive scenario
10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
10.8. Latin America
10.8.1. Latin America: SWOT Analysis
10.8.2. Brazil
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework
10.8.2.3. Competitive scenario
10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
10.8.3. Argentina
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework
10.8.3.3. Competitive scenario
10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
10.9. MEA
10.9.1. MEA: SWOT Analysis
10.9.2. South Africa
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework
10.9.2.3. Competitive scenario
10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
10.9.3. Saudi Arabia
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework
10.9.3.3. Competitive scenario
10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
10.9.4. UAE
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework
10.9.4.3. Competitive scenario
10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
10.9.5. Kuwait
10.9.5.1. Key country dynamics
10.9.5.2. Regulatory framework
10.9.5.3. Competitive scenario
10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Recent Developments & Impact Analysis, By Key Market Participants
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2024
11.3.4. BIOMEDOMICS INC.
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Services benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Silver Lake Research Corporation
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Services benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Bio-Rad Laboratories, Inc.
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Services benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Trivitron Healthcare
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Services benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Hemex Health
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Services benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Sysmex Corporation
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Services benchmarking
11.3.9.4. Strategic initiatives
11.3.10. EKF Diagnostics Holdings plc.
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Services benchmarking
11.3.10.4. Strategic initiatives
11.3.11. HemoCue America (Danaher)
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Services benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Services benchmarking
11.3.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. Age group
1.2.4. Sector Type
1.2.5. End Use
1.2.6. Distribution Channel
1.2.7. Regional scope
1.2.8. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Technology Outlook
2.2.3. Age Group Outlook
2.2.4. Sector Type
2.2.5. End Use Outlook
2.2.6. Distribution Channel
2.2.7. Regional outlook
2.3. Competitive Insights
CHAPTER 3. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for personalized medicine and genomic research
3.2.1.2. Growing prevalence of sickle cell disease (SCD)
3.2.1.3. Advancements in diagnostic technology
3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
3.2.2. Market restraint analysis
3.2.2.1. Limited accessibility to advanced technologies
3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Lateral Flow Immunoassay
4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Paper-Based Rapid Diagnostics
4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Others
4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hemoglobin Electrophoresis
5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Polymerase Chain Reaction (PCR)
5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Isothermal Amplification Assays
5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Newborn Screening (12 months and below)
6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Adult Screening (25 to 60 years)
6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Other Age Groups (1 to 25 & Above 60 years)
6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: SECTOR TYPE ESTIMATES & TREND ANALYSIS
7.1. Sector Type Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Government Labs
7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Private Labs
7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Corporate Labs
7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. PPP (Public-Private-Partnerships)
7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. End Use Market Share, 2024 & 2030
8.2. Segment Dashboard
8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Research Institutions
8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Hospitals & Clinics
8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. Diagnostic Laboratories
8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Homecare Settings
8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Others
8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
9.1. Distribution Channel Market Share, 2024 & 2030
9.2. Segment Dashboard
9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
9.4.1. B2B (Business-to-Business)
9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
9.4.2. B2C (Business-to-Consumer)
9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 10. RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. North America: SWOT Analysis
10.5.2. U.S.
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework
10.5.2.3. Competitive scenario
10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
10.5.3. Canada
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework
10.5.3.3. Competitive scenario
10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.5.4. Mexico
10.5.4.1. Key country dynamics
10.5.4.2. Regulatory framework
10.5.4.3. Competitive scenario
10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.6. Europe
10.6.1. Europe: SWOT Analysis
10.6.2. UK
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework
10.6.2.3. Competitive scenario
10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
10.6.3. Germany
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework
10.6.3.3. Competitive scenario
10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
10.6.4. France
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework
10.6.4.3. Competitive scenario
10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
10.6.5. Italy
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework
10.6.5.3. Competitive scenario
10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
10.6.6. Spain
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework
10.6.6.3. Competitive scenario
10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
10.6.7. Norway
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework
10.6.7.3. Competitive scenario
10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
10.6.8. Sweden
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework
10.6.8.3. Competitive scenario
10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
10.6.9. Denmark
10.6.9.1. Key country dynamics
10.6.9.2. Regulatory framework
10.6.9.3. Competitive scenario
10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
10.7. Asia Pacific
10.7.1. Asia Pacific: SWOT Analysis
10.7.2. Japan
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework
10.7.2.3. Competitive scenario
10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
10.7.3. China
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework
10.7.3.3. Competitive scenario
10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
10.7.4. India
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework
10.7.4.3. Competitive scenario
10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
10.7.5. Australia
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework
10.7.5.3. Competitive scenario
10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
10.7.6. South Korea
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework
10.7.6.3. Competitive scenario
10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
10.7.7. Thailand
10.7.7.1. Key country dynamics
10.7.7.2. Regulatory framework
10.7.7.3. Competitive scenario
10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
10.8. Latin America
10.8.1. Latin America: SWOT Analysis
10.8.2. Brazil
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework
10.8.2.3. Competitive scenario
10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
10.8.3. Argentina
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework
10.8.3.3. Competitive scenario
10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
10.9. MEA
10.9.1. MEA: SWOT Analysis
10.9.2. South Africa
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework
10.9.2.3. Competitive scenario
10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
10.9.3. Saudi Arabia
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework
10.9.3.3. Competitive scenario
10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
10.9.4. UAE
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework
10.9.4.3. Competitive scenario
10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
10.9.5. Kuwait
10.9.5.1. Key country dynamics
10.9.5.2. Regulatory framework
10.9.5.3. Competitive scenario
10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Recent Developments & Impact Analysis, By Key Market Participants
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2024
11.3.4. BIOMEDOMICS INC.
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Services benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Silver Lake Research Corporation
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Services benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Bio-Rad Laboratories, Inc.
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Services benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Trivitron Healthcare
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Services benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Hemex Health
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Services benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Sysmex Corporation
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Services benchmarking
11.3.9.4. Strategic initiatives
11.3.10. EKF Diagnostics Holdings plc.
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Services benchmarking
11.3.10.4. Strategic initiatives
11.3.11. HemoCue America (Danaher)
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Services benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Services benchmarking
11.3.12.4. Strategic initiatives
LIST OF TABLES
Table 1 List of Abbreviations
Table 2 List of Secondary Sources
Table 3 Regulatory Framework
Table 4 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Region, 2018 – 2030 (USD Million)
Table 5 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 6 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 – 2030 (USD Million)
Table 7 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 USD Million
Table 8 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 9 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 10 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 – 2030 (USD Million)
Table 11 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 12 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 13 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 14 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 – 2030 (USD Million)
Table 15 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 16 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 17 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 – 2030 (USD Million)
Table 18 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 19 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 20 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 – 2030 (USD Million)
Table 21 U.S Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 22 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 23 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 24 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 25 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 26 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 27 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 28 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 29 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 31 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 32 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 33 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 34 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 35 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 37 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 38 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 39 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 40 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 41 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 42 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 44 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 45 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 46 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 47 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 48 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 50 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 51 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 52 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 53 Germany America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 54 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 56 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 57 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 58 France Rapid Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 59 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 60 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 62 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 63 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 64 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 65 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 66 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 68 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 70 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 71 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 72 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 74 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 75 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 76 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 77 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 78 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 79 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 81 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 82 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 83 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 84 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 85 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 86 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 87 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 88 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 89 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 90 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 91 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 92 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 93 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 94 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 95 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 96 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 97 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 98 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 99 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 100 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 101 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 102 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 103 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 104 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 105 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 106 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 107 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 108 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 109 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 110 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 111 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 112 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 113 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 114 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 115 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 116 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 117 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 118 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 119 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 120 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 121 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 122 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 123 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 124 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 125 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 126 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 127 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 128 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 129 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 130 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 131 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 132 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 133 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 134 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 135 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 136 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 137 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 138 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 139 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 140 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 141 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 142 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 143 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 144 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 145 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 146 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 147 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million) million
Table 148 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 149 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 151 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 152 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 153 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 1 List of Abbreviations
Table 2 List of Secondary Sources
Table 3 Regulatory Framework
Table 4 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Region, 2018 – 2030 (USD Million)
Table 5 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 6 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 – 2030 (USD Million)
Table 7 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 USD Million
Table 8 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 9 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 10 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 – 2030 (USD Million)
Table 11 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 12 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 13 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 14 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 – 2030 (USD Million)
Table 15 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 16 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 17 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 – 2030 (USD Million)
Table 18 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 19 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 20 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 – 2030 (USD Million)
Table 21 U.S Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 22 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 23 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 24 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 25 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 26 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 27 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 28 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 29 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 31 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 32 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 33 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 34 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 35 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 37 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 38 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 39 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 40 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 41 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 42 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 44 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 45 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 46 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 47 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 48 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 50 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 51 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 52 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 53 Germany America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 54 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 56 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 57 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 58 France Rapid Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 59 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 60 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 62 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 63 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 64 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 65 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 66 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 68 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 70 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 71 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 72 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 74 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 75 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 76 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 77 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 78 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 79 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 81 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 82 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 83 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 84 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 85 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 86 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 87 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 88 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 89 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 90 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 91 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 92 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 93 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 94 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 95 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 96 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 97 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 98 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 99 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 100 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 101 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 102 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 103 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 104 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 105 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 106 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 107 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 108 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 109 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 110 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 111 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 112 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 113 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 114 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 115 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 116 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 117 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 118 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 119 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 120 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 121 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 122 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 123 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 124 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 125 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 126 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 127 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 128 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 129 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
Table 130 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 131 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 132 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 133 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 134 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 135 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 136 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 137 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 138 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 139 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 140 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 141 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 142 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 143 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 144 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 145 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 146 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 147 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million) million
Table 148 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
Table 149 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
Table 151 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
Table 152 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
Table 153 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Rapid Point-of-Care Testing for Sickle Cell Anemia: market outlook
Fig. 14 Rapid Point-of-Care Testing for Sickle Cell Anemia competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook.
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Rapid Point-of-Care Testing for Sickle Cell Anemia driver impact
Fig. 20 Rapid Point-of-Care Testing for Sickle Cell Anemia restraint impact
Fig. 21 Rapid Point-of-Care Testing for Sickle Cell Anemia strategic initiatives analysis
Fig. 22 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type movement analysis
Fig. 23 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type outlook and key takeaways
Fig. 24 Lateral Flow Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Paper-Based Rapid Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology movement analysis
Fig. 28 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology outlook and key takeaways
Fig. 29 Hemoglobin Electrophoresis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Isothermal Amplification Assays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group movement analysis
Fig. 34 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group outlook and key takeaways
Fig. 35 Newborn Screening (12 months and below) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Adult Screening (25 to 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Other Age Groups (1 to 25 & Above 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type movement analysis
Fig. 39 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type outlook and key takeaways
Fig. 40 Government Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Private Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Corporate Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 PPP (Public-Private-Partnerships) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use movement analysis
Fig. 45 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use outlook and key takeaways
Fig. 46 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Research Institutions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Homecare Settings market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution movement analysis
Fig. 52 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution Channel outlook and key takeaways
Fig. 53 B2B (Business-to-Business) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 B2C (Business-to-Consumer) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Global rapid point-of-care testing for sickle cell anemia market: Regional movement analysis
Fig. 56 Global rapid point-of-care testing for sickle cell anemia market: Regional outlook and key takeaways
Fig. 57 Global rapid point-of-care testing for sickle cell anemia market shares and leading players
Fig. 58 North America
Fig. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 U.S.
Fig. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Canada
Fig. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Mexico
Fig. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Europe
Fig. 67 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 UK
Fig. 69 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Germany
Fig. 71 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 France
Fig. 73 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Italy
Fig. 75 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Spain
Fig. 77 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Denmark
Fig. 79 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Sweden
Fig. 81 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Norway
Fig. 83 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Asia Pacific
Fig. 85 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 China
Fig. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Japan
Fig. 89 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 India
Fig. 91 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Thailand
Fig. 93 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 South Korea
Fig. 95 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Australia
Fig. 97 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Latin America
Fig. 99 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Brazil
Fig. 101 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Argentina
Fig. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Middle East and Africa
Fig. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 106 South Africa
Fig. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 108 Saudi Arabia
Fig. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 110 UAE
Fig. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 112 Kuwait
Fig. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 114 Market share of key market players- Rapid Point-of-Care Testing for Sickle Cell Anemia
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Rapid Point-of-Care Testing for Sickle Cell Anemia: market outlook
Fig. 14 Rapid Point-of-Care Testing for Sickle Cell Anemia competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook.
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Rapid Point-of-Care Testing for Sickle Cell Anemia driver impact
Fig. 20 Rapid Point-of-Care Testing for Sickle Cell Anemia restraint impact
Fig. 21 Rapid Point-of-Care Testing for Sickle Cell Anemia strategic initiatives analysis
Fig. 22 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type movement analysis
Fig. 23 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type outlook and key takeaways
Fig. 24 Lateral Flow Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Paper-Based Rapid Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology movement analysis
Fig. 28 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology outlook and key takeaways
Fig. 29 Hemoglobin Electrophoresis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Isothermal Amplification Assays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group movement analysis
Fig. 34 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group outlook and key takeaways
Fig. 35 Newborn Screening (12 months and below) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Adult Screening (25 to 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Other Age Groups (1 to 25 & Above 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type movement analysis
Fig. 39 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type outlook and key takeaways
Fig. 40 Government Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Private Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Corporate Labs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 PPP (Public-Private-Partnerships) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use movement analysis
Fig. 45 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use outlook and key takeaways
Fig. 46 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Research Institutions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Homecare Settings market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution movement analysis
Fig. 52 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution Channel outlook and key takeaways
Fig. 53 B2B (Business-to-Business) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 B2C (Business-to-Consumer) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Global rapid point-of-care testing for sickle cell anemia market: Regional movement analysis
Fig. 56 Global rapid point-of-care testing for sickle cell anemia market: Regional outlook and key takeaways
Fig. 57 Global rapid point-of-care testing for sickle cell anemia market shares and leading players
Fig. 58 North America
Fig. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 U.S.
Fig. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Canada
Fig. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Mexico
Fig. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Europe
Fig. 67 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 UK
Fig. 69 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Germany
Fig. 71 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 France
Fig. 73 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Italy
Fig. 75 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Spain
Fig. 77 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Denmark
Fig. 79 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Sweden
Fig. 81 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Norway
Fig. 83 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Asia Pacific
Fig. 85 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 China
Fig. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Japan
Fig. 89 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 India
Fig. 91 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Thailand
Fig. 93 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 South Korea
Fig. 95 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Australia
Fig. 97 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Latin America
Fig. 99 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Brazil
Fig. 101 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Argentina
Fig. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Middle East and Africa
Fig. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 106 South Africa
Fig. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 108 Saudi Arabia
Fig. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 110 UAE
Fig. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 112 Kuwait
Fig. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 114 Market share of key market players- Rapid Point-of-Care Testing for Sickle Cell Anemia
